No. Zepbound contains tirzepatide; Ozempic injection contains semaglutide. Tirzepatide acts on GIP and GLP-1 receptors, while semaglutide acts on GLP-1 receptors. They have different approved uses and delivery presentations.
This guide compares Zepbound with Ozempic injection. It uses U.S. sources checked on October 2, 2026, including Zepbound prescribing information revised August 2026 and Ozempic injection prescribing information revised May 2026.
Novo Nordisk also lists Ozempic tablets in the U.S. They have a separate label. Do not transfer injection directions or indications to tablets. Confirm the prescribed formulation with your clinician or pharmacist.
Zepbound vs Ozempic injection: the main differences
| Detail | Zepbound | Ozempic injection |
|---|---|---|
| Ingredient | Tirzepatide | Semaglutide |
| Receptors | GIP and GLP-1 | GLP-1 |
| Approved weight-management use | Yes, in specified adult groups | No |
| Other approved uses | Moderate-to-severe obstructive sleep apnea in adults with obesity | Adult type 2 diabetes; cardiovascular risk reduction also requires established cardiovascular disease; kidney-related risk reduction also requires chronic kidney disease |
| Route | Injection under the skin | Injection under the skin |
| Label-listed presentations | Single-dose pens/vials, multi-dose vials, KwikPens | Single-patient-use pens, single-dose prefilled syringes |
See the Zepbound label and Ozempic injection label. The table is a comparison, not a complete prescribing guide. Both labels address adults; pediatric safety and effectiveness have not been established.
What is Zepbound approved for?
The FDA's original weight-management approval covers adults with obesity, described as BMI of at least 30, or overweight, described as BMI of at least 27 with a weight-related condition. The current label covers weight reduction and long-term maintenance, alongside diet and activity changes.
The separate sleep-apnea approval covers moderate-to-severe obstructive sleep apnea in adults with obesity. Keep the qualifying conditions together: an approval for a defined group is not approval for everyone who wants to lose weight or has trouble sleeping.
What is Ozempic injection approved for?
Ozempic injection's label covers blood sugar control in adults with type 2 diabetes. Its additional indications have qualifying conditions: cardiovascular risk reduction requires type 2 diabetes and established cardiovascular disease; kidney-related risk reduction requires type 2 diabetes and chronic kidney disease.
The kidney indication concerns sustained kidney-function decline, end-stage kidney disease and cardiovascular death. Those outcomes should not become a general promise about protecting every person's kidneys or heart.
The FDA's February 2026 Ozempic advertising letter addresses this exact distinction. It also explains why counting approved uses does not establish superiority over other GLP-1 medicines.
Ozempic injection is not FDA-approved for weight loss. That identifies its approved use, rather than saying weight changes cannot occur. Ask which diagnosis a proposed prescription is intended to treat.
Are their devices interchangeable?
No. Use the presentation named on your own prescription and packaging. The current Ozempic injection label includes syringes as well as pens, so pen-only descriptions are outdated. The Zepbound KwikPen guide discusses that specific presentation.
A label listing does not confirm pharmacy stock. Before filling a prescription, ask the pharmacist to identify the exact device, provide its instructions and explain anything you do not understand. Do not apply directions from another product merely because the devices look similar.
What safety differences need a conversation?
Both have a boxed warning about thyroid C-cell tumors observed in rodents; human relevance is unknown. Contraindications include a personal or family history of medullary thyroid carcinoma, MEN 2, and serious allergy to the respective product. This is more specific than every thyroid condition.
Their labels also describe severe gastrointestinal reactions and other important risks, including pancreatitis, gallbladder events, dehydration-related kidney injury, hypoglycemia with certain diabetes medicines, retinopathy and aspiration during anesthesia. Both are not recommended in severe gastroparesis.
Discuss pregnancy plans, other medicines and planned procedures with your clinician. Zepbound can affect birth control pills. Read the full prescribing information and your product's Medication Guide; this comparison does not reproduce all safety information.
What should you ask before choosing or changing treatment?
Zepbound's label does not recommend combining it with a GLP-1 receptor agonist, including Ozempic. Do not combine or exchange medicines on your own.
Bring your current medicine list and ask:
- Which approved use matches the condition we are treating?
- What in my history makes this option appropriate or unsuitable?
- Which exact presentation will I receive, and who explains how to use it?
- What symptoms require a call or urgent assessment?
- If you recommend a change, what written plan should I follow?
- What follow-up is planned, and who should I contact with concerns?
- Does my quoted cost refer to that exact presentation, and what has my insurer confirmed?
For price questions, use the Zepbound cost quote worksheet.
Write down the answers, including the product name, the reason it was chosen and the contact for follow-up. If the explanation you receive conflicts with the prescription or packaging, ask the prescriber or pharmacist to resolve it. The useful outcome is an understandable plan for your situation, rather than a universal winner between brands.
Educational information only, not individual medical advice. Labels and availability can change. Talk with your prescriber before starting, stopping, combining or changing prescription medicines.
Frequently Asked Questions
Do Zepbound and Ozempic contain different active ingredients?
Yes. Zepbound contains tirzepatide, which acts on GIP and GLP-1 receptors. Ozempic contains semaglutide, which acts on GLP-1 receptors.
Is Ozempic injection FDA-approved for weight loss?
No. Its approved uses concern adult type 2 diabetes and specified cardiovascular and kidney risk-reduction indications, with qualifying conditions.
Can you take Zepbound and Ozempic together?
Zepbound's label does not recommend combining it with a GLP-1 receptor agonist, including Ozempic. Discuss your treatment with your prescriber.
Are Zepbound and Ozempic injection available only as pens?
No. Zepbound's label includes pen and vial presentations; Ozempic injection's includes pens and prefilled syringes. Ozempic tablets have a separate label. Confirm the prescribed formulation and availability with your pharmacy.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.Zepbound prescribing information, revised August 2026, sections 1, 3, 4, 5, 7.2, 8 and 12.1 · Eli Lilly and Company · accessed
- 2.Ozempic injection prescribing information, revised May 2026, sections 1, 3, 4, 5, 8 and 12.1 · Novo Nordisk · accessed
- 3.FDA approves Zepbound for chronic weight management, November 8, 2023 · U.S. Food and Drug Administration · accessed
- 4.FDA approves Zepbound for obstructive sleep apnea, December 20, 2024 · U.S. Food and Drug Administration · accessed
- 5.FDA Ozempic promotional communication letter, February 26, 2026 · U.S. Food and Drug Administration · accessed
- 6.Novo Nordisk U.S. diabetes product listing, including Ozempic injection and tablets · Novo Nordisk · accessed
- 7.FDA labeling for Rybelsus and Ozempic tablets, revised January 2026; separate from Ozempic injection · U.S. Food and Drug Administration · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them